Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CytoSen Therapeutics
Houston, TX, USAcytosen.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
CytoSen Therapeutics was a clinical-stage biotechnology company focused on developing next-generation natural killer (NK) cell therapies for cancer. The company's proprietary FC21 platform utilized plasma membrane particles to expand and activate high-dose NK cells with enhanced anti-tumor activity. CytoSen's lead programs targeted hematological malignancies, including acute myeloid leukemia and myelodysplastic syndrome. In 2019, the company was acquired by Kiadis Pharma to combine its NK cell expansion technology with Kiadis's cell therapy pipeline. Following Kiadis's acquisition by Sanofi in 2021, the technology is now part of Sanofi's oncology portfolio.
- Therapeutic areas
- HematologyOncology
- Modalities
- NK cell therapyCell therapy
- Industry
- Biotech
Beyond the preview
Go deeper on CytoSen Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CytoSen Therapeutics.